Vivek Kumaravel is a Product Manager at Syngene International Limited with extensive experience in pharmaceutical development, specializing in generics and NDA/505(b)(2) filings across global markets. With expertise in Phase 1 formulation and late-phase programs, Vivek has overseen the development of different dosage forms and animal health products. With close to 20 years of experience at different companies like Sun Pharma, Novartis Healthcare and Ranbaxy Laboratories, Vivek has developed strategies for Para IV/FTF/505(b)(2) filings and worked on abuse-deterrent platform technologies. He has contributed to multiple programs, and has 4 approved 505(b)(2) applications, 1 approved NDA, 12 patent applications, and has authored 4 international research publications.